Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Descovy (emtricitabine + tenofovir alafenamide)

Descovy

Generic name: emtricitabine (also known as FTC) and tenofovir alafenamide (TAF)

Brand names: Descovy

Class: Combined NRTI (nukes) tablets

Side-effects:

Common: Nausea.


Rare: Lactic acidosis, serious liver problems (the first two side effects are most likely in very overweight women or those who have been taking Descovy or similar medicines for a long time), worsening of hepatitis B when stopping Descovy (see Notes), body fat redistribution, immune reconstitution inflammatory syndrome (IRIS), renal impairment, decrease in bone mineral density, mineralisation defects.

Dosage:

Tablet comprises 200mg emtricitabine plus 25mg or 10mg tenofovir alafenamide (TAF).

Taken once per day.

Notes:

Descovy is licensed for use once per day with at least one other antiretroviral.

When taken with ritonavir or cobicistat-boosted atazanavir, lopinavir or darunavir (protease inhibitors), the tablet containing 10mg of tenofovir alafenamide (TAF) is recommended.

Special monitoring may be needed in patients co-infected with HIV and hepatitis B as Descovy is not licenced to treat the latter. If you're taking Descovy and then stop, it could cause your hepatitis B to worsen.

Descovy is not recommended in patients with severe renal impairment.

Take with or without food.


*Last reviewed on 2/12/2016 Next review: 2/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM